CepTor Corporation to Present at the Rodman & Renshaw Techvest 2nd Annual Global Health Conference.HUNT VALLEY, Md. -- CepTor Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CEPO CEPO County Emergency Planning Officer (UK) CEPO Community & Environment Project Office (Edmonton Green, North London) ) today announced that it will be participating in the Rodman & Renshaw Techvest 2nd Annual Global Health Conference, to be held May 4 - 5, 2005 at the InterContinental Hotel in Paris, France. William Pursley, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CepTor, is scheduled to speak on Wednesday, May 4, 2005 at 9:05 AM local time (3:05 AM EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) and is expected to discuss the Company's product pipeline, strategic initiatives and market opportunities. CepTor's audio presentation will be broadcast live over the Internet. To access the audio webcast, please log onto http://www.wsw.com/webcast/rrshq5/cepo/. The link will be active 90 days after the presentation and is for both the live event and the archive. About CepTor Corporation CepTor Corporation is a biopharmaceutical company focusing on the development of proprietary, cell-targeted therapeutic products for neuromuscular neuromuscular /neu·ro·mus·cu·lar/ (-mus´ku-ler) pertaining to nerves and muscles, or to the relationship between them. neu·ro·mus·cu·lar adj. 1. and neurodegenerative diseases neurodegenerative diseases diseases characterized by neurodegeneration. Lesions are microscopic only but in chronic disease with massive involvement there may be grossly visible atrophy of affected nervous tissue. . The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne's muscular dystrophy Duchenne's muscular dystrophy, n an X-linked recessive condition pres-ent at birth in which the muscles of the pelvis and legs waste away in a symmetric fashion. . The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy. This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. We are in the early stages of drug discovery and development. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement. As is always the case with early stage companies, we will also be affected by factors involving continued access to capital. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion